Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -23.45 is 98% above its 5-year average of -1526.80, near the high end of its 5-year range (-7095.17–-23.45).
39.66% above its 12-month average of -38.87.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -3.50.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 30 comparable quarters.
EARNINGS PER SHARE (EPS)
-23.45
EARNINGS PER SHARE (EPS) AVG TTM
-38.87
EARNINGS PER SHARE (EPS) AVG 3Y
-195.80
EARNINGS PER SHARE (EPS) AVG 5Y
-1526.80
EARNINGS PER SHARE (EPS) AVG 10Y
-2524.14
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+39.66%
CURRENT VS 3Y AVG
+88.02%
CURRENT VS 5Y AVG
+98.46%
CURRENT VS 10Y AVG
+99.07%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Yarrow Bioscience Inc
Market Cap
$177.62M
Earnings Per Share (EPS)
-23.45
TTM Avg
-38.87
3Y Avg
-195.80
5Y Avg
-1526.80
Market Cap
$177.73M
Earnings Per Share (EPS)
-0.41
TTM Avg
-0.39
3Y Avg
-0.36
5Y Avg
-0.55
Market Cap
$174.29M
Earnings Per Share (EPS)
-0.46
TTM Avg
-0.40
3Y Avg
-0.54
5Y Avg
-0.73
Market Cap
$181.61M
Earnings Per Share (EPS)
4.11
TTM Avg
0.53
3Y Avg
0.05
5Y Avg
-0.11
Market Cap
$173.31M
Earnings Per Share (EPS)
-0.23
TTM Avg
-0.59
3Y Avg
-0.77
5Y Avg
-0.88
Market Cap
$184.71M
Earnings Per Share (EPS)
-1.57
TTM Avg
-5.27
3Y Avg
-99.59
5Y Avg
-93.21
Market Cap
$171.00M
Earnings Per Share (EPS)
-27.00
TTM Avg
-15.00
3Y Avg
-27.00
5Y Avg
-32.85
Market Cap
$184.40M
Earnings Per Share (EPS)
-1.07
TTM Avg
-1.44
3Y Avg
-2.10
5Y Avg
-1.78
Market Cap
$170.32M
Earnings Per Share (EPS)
-2.80
TTM Avg
-1.25
3Y Avg
-14.14
5Y Avg
-22.50
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Yarrow Bioscience Inc (YARW) | $177.62M | -23.45 | -38.87 | -195.80 | -1526.80 |
| Compass Therapeutics, Inc. (CMPX)vs › | $177.73M | -0.41 | -0.39 | -0.36 | -0.55 |
| ProQR Therapeutics N.V. (PRQR)vs › | $174.29M | -0.46 | -0.40 | -0.54 | -0.73 |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $181.61M | 4.11 | 0.53 | 0.05 | -0.11 |
| Journey Medical Corporation (DERM)vs › | $173.31M | -0.23 | -0.59 | -0.77 | -0.88 |
| Canton Strategic Holdings Inc (CNTN)vs › | $184.71M | -1.57 | -5.27 | -99.59 | -93.21 |
| Cue Biopharma, Inc. (CUE)vs › | $171.00M | -27.00 | -15.00 | -27.00 | -32.85 |
| AN2 Therapeutics, Inc. (ANTX)vs › | $184.40M | -1.07 | -1.44 | -2.10 | -1.78 |
| Precision BioSciences, Inc. (DTIL)vs › | $170.32M | -2.80 | -1.25 | -14.14 | -22.50 |
| Organogenesis Holdings Inc. (ORGO)vs › | $169.21M | -0.83 | 0.02 | 0.22 | 0.10 |
Trailing EPS (TTM)
$-23.45
Forward EPS (Est.)
$-89.00
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -30.96 |
| 2024-12-31 | -46.77 |
| 2023-12-31 | -138.48 |
| 2022-12-31 | -566.98 |
| 2021-12-31 | -1282.44 |
| 2020-12-31 | -7095.17 |
| 2018-12-31 | -8546.98 |
| 2017-12-31 | -4555.37 |
| 2016-12-31 | -2204.06 |
| 2015-12-31 | -774.18 |
